

## **Transgene's monoclonal antibody drug demonstrates unique effect against three cancers**

May 12, 2010

Transgene declared today that one of its therapeutic monoclonal antibodies (mAb), which was originally developed for Colon Cancer, has demonstrated remarkable and exciting efficacy against two additional cancers also, namely Multiple Myeloma and Non-Hodgkin's Lymphoma. So far, there is no other known monoclonal drug in the world that has demonstrated a similar therapeutic effect against all three cancers.

Conceived in early 2007, the invention of this drug was based on the discovery of a unique cell surface antigen that is expressed on Colon Cancer, Multiple Myeloma and Non-Hodgkin's Lymphoma cancer cells. This discovery facilitated the development of a targeted drug 'TBL-0306' which specifically killed the three stated types of cancer cells while sparing normal cells and healthy tissues, unlike conventional chemotherapy that has detrimental effects on the normal cells.

Colon Cancer is quite common in men and women. It is reported that by 2020, 9.7% of new cases of cancer in the world will be from Colorectal Cancer, making it the 3<sup>rd</sup> highest incidence cancer after Lung and Breast.

Multiple Myeloma is a malignant tumor of a type of white blood cell (the plasma cell) and it is the 2<sup>nd</sup> most common cancer of the blood. Multiple Myeloma accounts for approximately 1% of all cancers and 2% of all deaths from cancer.

Non-Hodgkin's Lymphoma (NHL) is the 6<sup>th</sup> most common cancer among males and the 5<sup>th</sup> most common cancer among females. Furthermore, the incidence of non-

Hodgkin's Lymphoma (NHL) has doubled over the past two decades in the US and most other western countries.

Armed with the remarkable and unique efficacy of its mAb based drug against three different cancers – Colon Cancer, Multiple Myeloma and Non-Hodgkin's Lymphoma, Transgene has initiated steps to advance this drug rapidly to the stage of pre-clinical and clinical studies immediately after complete humanization.

As reported earlier, this monoclonal-based platform is the second unique oncology technology platform in the development pipeline at Transgene. The first oncology platform employs RNAi, designed on the basis of genetically modified and novel AAV vectors, for effective and efficient delivery of chosen and proprietary siRNAs to specific gene targets. This novel and patented RNAi platform has been employed in developing Transgene's first line of drugs against Liver and metastasizing Breast Cancers.